FY2025 EPS Estimates for Belite Bio Decreased by Analyst

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will post earnings of ($1.48) per share for the year, down from their previous estimate of ($1.36). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Several other research firms have also commented on BLTE. Wall Street Zen lowered Belite Bio from a "hold" rating to a "sell" rating in a research report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Belite Bio in a research note on Thursday, May 15th. Finally, Benchmark reiterated a "buy" rating and issued a $80.00 price target on shares of Belite Bio in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Belite Bio currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.67.

Belite Bio Stock Performance

Belite Bio stock traded down $3.63 during midday trading on Monday, reaching $61.00. 27,818 shares of the company were exchanged, compared to its average volume of 49,780. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -54.95 and a beta of -1.48. The firm's 50-day simple moving average is $61.42 and its 200-day simple moving average is $62.82. Belite Bio has a 1 year low of $43.70 and a 1 year high of $86.53.

Institutional Investors Weigh In On Belite Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisors Preferred LLC acquired a new position in Belite Bio during the fourth quarter valued at approximately $52,000. GAMMA Investing LLC lifted its holdings in Belite Bio by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock worth $122,000 after buying an additional 559 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Belite Bio during the 4th quarter valued at about $155,000. JPMorgan Chase & Co. raised its stake in Belite Bio by 7,122.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company's stock worth $298,000 after buying an additional 6,268 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock worth $446,000 after purchasing an additional 1,668 shares during the last quarter. Institutional investors own 0.53% of the company's stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.